PDCD1 and neoplasm: When targeting the PD-1/PD-L1 axis on the basis of local RT, it broke the limitation, activated the systemic immunity to exert a distal anti-tumor ability, and extended the expression of PD-L1 on the tumor cells and MDSCs in non-radiation lesions [73].